Abstract:Dengue, caused by dengue virus (DENV), is now endemic in nearly 100 countries and infection incidence is reported in another 30 countries. Yearly an estimated 400 million cases and 2200 deaths are reported. Effective vaccines against DENV are limited and there has been significant focus on the development of effective antiviral against the disease. The World Health Organization has initiated research programs to prioritize the development and optimization of antiviral agents against several viruses including Flaviviridae. A significant effort has been taken by the researchers to develop effective antivirals against DENV. Several potential small-molecule inhibitors like efavirenz, tipranavir and dasabuvir have been tested against envelope and non-structural proteins of DENV, and are in clinical trials around the world. We recently developed one small molecule, namely 7D, targeting the host PF4-CXCR3 axis. 7D inhibited all 4 serotypes of DENV in vitro and specifically DENV2 infection in two different mice models. Although the development of dengue vaccines remains a high priority, antibody cross reactivity among the serotypes and resulting antibody-dependent enhancement (ADE) of infection are major concerns that have limited the development of effective vaccine against DENV. Therefore, there has been a significant emphasis on the development of antiviral drugs against dengue. This review article describes the rescue effects of some of the small molecule inhibitors to viral/host factors associated with DENV pathogenesis.

Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses

New perspective of small-molecule antiviral drugs development for RNA viruses

Antivirals with common targets against highly pathogenic viruses

Development of Small-Molecule Inhibitors Against Zika Virus Infection

Therapeutic strategies to target the Ebola virus life cycle

Recent advances in developing small-molecule inhibitors against SARS-CoV-2

Repurposing host-based therapeutics to control coronavirus and influenza virus

Multidisciplinary approaches to combat emerging viruses: diagnostics, therapeutic gene and vaccine delivery, and nanotherapeutics

Current Progress in Antiviral Strategies.

Development of Small-Molecule MERS-CoV Inhibitors.

Antiviral Agents against Flavivirus Protease: Prospect and Future Direction

An update review of emerging small-molecule therapeutic options for COVID-19

Defeating Enemy Outside the Border-Development of Viral Entry Inhibitors

Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection

A Mini-Review on the Common Antiviral Drug Targets of Coronavirus

Recent Advances on Targeting Proteases for Antiviral Development

Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells

Medicinal chemistry strategies toward broad-spectrum antiviral agents to prevent next pandemics

Pan‐coronavirus Fusion Inhibitors to Combat COVID‐19 and Other Emerging Coronavirus Infectious Diseases

Dengue virus: pathogenesis and potential for small molecule inhibitors

Receptor-Binding Domains Of Spike Proteins Of Emerging Or Re-Emerging Viruses As Targets For Development Of Antiviral Vaccines